An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
There’s growing evidence that some people with eating disorders are using Ozempic (a weight-loss diabetes drug) in ways that are harmful. Reports and social-media posts show people with anorexia, bulimia, or other disordered-eating behaviors are taking the drug to suppress appetite or speed weight loss, often without medical oversight. Health professionals and advocacy groups are raising alarms because this use is risky and not part of how the drug is meant to be used. Ozempic’s active ingredient is semaglutide. Semaglutide is a man-made version of a hormone your gut releases after you eat. That hormone talks to the brain to reduce hunger and slow how fast your stomach empties, which can make you feel full longer. Ozempic was developed for treating type 2 diabetes, and similar semaglutide doses are prescribed under different brand names for chronic weight management. It’s not a magic pill; it changes signals in the body that reduce appetite. The reports aren’t from one big clinical trial but from news coverage, clinicians’ observations, and social-media accounts. Those sources describe people with eating disorders using semaglutide to help them eat less or avoid recovery goals. The coverage suggests this use can produce strong appetite suppression and weight loss, which is exactly why some people are drawn to it. But these are case reports and anecdotal patterns, not controlled studies proving safety or benefit in people with eating disorders. We don’t have rigorous data showing outcomes, long-term effects, or how common this behavior is. Why this matters: treating eating disorders is complicated and involves restoring healthy eating, body weight, and mental health. A drug that bluntly reduces appetite can make it easier to avoid eating and harder to follow treatment plans. That can worsen medical complications and make recovery harder. Clinicians, friends, and family of people with eating disorders should know that appetite-suppressing medications can be misused and can interfere with therapy and medical monitoring. There are real risks and unknowns. Semaglutide can cause nausea, stomach problems, dizziness, and, in rare cases, more serious issues like pancreatitis (inflammation of the pancreas). For people with eating disorders, there’s extra danger: using it without medical supervision can hide how much someone is restricting food, delay needed treatment, and worsen heart or bone health that’s already vulnerable. Semaglutide is prescription-only and meant to be used under a doctor’s supervision for approved conditions; using it off-label or obtaining it without a prescription is unsafe. If someone with an eating disorder is using or considering this drug, they should be encouraged to talk to their treatment team or a medical professional. Bottom line: Ozempic can strongly reduce appetite, and some people with eating disorders are misusing it to lose weight — a practice that’s risky, not supported by evidence, and likely to interfere with proper treatment.
Source: Gizmodo